[go: up one dir, main page]

GT200900310A - Macrociclos y sus usos - Google Patents

Macrociclos y sus usos

Info

Publication number
GT200900310A
GT200900310A GT200900310A GT200900310A GT200900310A GT 200900310 A GT200900310 A GT 200900310A GT 200900310 A GT200900310 A GT 200900310A GT 200900310 A GT200900310 A GT 200900310A GT 200900310 A GT200900310 A GT 200900310A
Authority
GT
Guatemala
Prior art keywords
macrociclos
compounds
manufacture
effective
treatment
Prior art date
Application number
GT200900310A
Other languages
English (en)
Inventor
Fujimoto Roger Aki
Krastel Philipp
Matthew J Lamarche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900310A publication Critical patent/GT200900310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS COMPUESTOS DE LA PRESENTE INVENCION SON ADECUADOS COMO AGENTES ACTIVOS EN COMPOSICIONES FARMACEUTICAS QUE SON EFICACES EN PARTICULAR PARA EL TRATAMIENTO DE INFECCIONES BACTERIANAS EN LAS QUE LA INVENCION PROPORCIONA ADICIONALMENTE METODO PARA LA FABRICACION DE UN MEDICAMENTO.
GT200900310A 2007-06-04 2009-12-02 Macrociclos y sus usos GT200900310A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94177707P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
GT200900310A true GT200900310A (es) 2010-05-21

Family

ID=40094226

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900310A GT200900310A (es) 2007-06-04 2009-12-02 Macrociclos y sus usos

Country Status (24)

Country Link
US (2) US8476224B2 (es)
EP (1) EP2170907A2 (es)
JP (1) JP2010529076A (es)
KR (1) KR101202483B1 (es)
CN (1) CN101772506B (es)
AR (1) AR066865A1 (es)
AU (1) AU2008258639B2 (es)
BR (1) BRPI0812340A2 (es)
CA (1) CA2688621A1 (es)
CL (1) CL2008001613A1 (es)
CO (1) CO6270222A2 (es)
CR (1) CR11158A (es)
EA (1) EA200901613A1 (es)
EC (1) ECSP099836A (es)
GT (1) GT200900310A (es)
IL (1) IL202285A0 (es)
MA (1) MA31562B1 (es)
MX (1) MX2009013214A (es)
NZ (1) NZ581917A (es)
PE (1) PE20090318A1 (es)
TN (1) TN2009000495A1 (es)
TW (1) TW200902540A (es)
WO (1) WO2008148754A2 (es)
ZA (1) ZA200908262B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2708793C (en) 2007-12-12 2016-06-21 Novartis Ag Aminothiazoles and their uses
WO2018073269A1 (en) * 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN109485617B (zh) * 2018-12-11 2023-01-31 贵州永诺菲特生物制药有限公司 一种n-甲基-2-异丙基-4-噻唑甲胺的制备方法
WO2024044751A2 (en) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Peroxiredoxin 3 inhibitors and methods of use for treating cancer
WO2025038747A1 (en) * 2023-08-14 2025-02-20 Rs Oncology, Llc Modified thiostrepton-inspired compounds for treatment of cancer and preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071143T3 (es) * 1990-03-08 1995-06-16 Lepetit Spa Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
DE9004073U1 (de) 1990-04-07 1990-06-13 Auto-Kabel Hausen GmbH & Co. Betriebs-KG, 79688 Hausen Anschlußklemme für Akkumulator o.dgl.
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
ATE163428T1 (de) * 1991-08-30 1998-03-15 Biosearch Italia Spa Faktor c2a des antibiotikums ce 2270
US6008225A (en) * 1996-02-14 1999-12-28 Biosearch Italia, S.P.A. Derivatives of antibiotic GE2270 factors C2a, D2 and E
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
EP1553967B1 (en) * 2002-06-17 2011-05-18 NAICONS s.c.a.r.l. Use of amide derivative of ge 2270 factor a3 for the treatment of acne
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
AR060977A1 (es) * 2006-05-31 2008-07-23 Novartis Ag Aminotiazoles y sus usos
EP2097423B1 (en) * 2006-12-20 2011-03-02 Novartis AG Aminothiazole macrocycles, their use as antibacterial compounds and processes for their production

Also Published As

Publication number Publication date
US20090186830A1 (en) 2009-07-23
ECSP099836A (es) 2010-01-29
CO6270222A2 (es) 2011-04-20
TN2009000495A1 (en) 2011-03-31
CA2688621A1 (en) 2008-12-11
US8691756B2 (en) 2014-04-08
CR11158A (es) 2010-01-20
IL202285A0 (en) 2010-06-16
AR066865A1 (es) 2009-09-16
TW200902540A (en) 2009-01-16
JP2010529076A (ja) 2010-08-26
MA31562B1 (fr) 2010-08-02
CN101772506A (zh) 2010-07-07
AU2008258639A1 (en) 2008-12-11
KR101202483B1 (ko) 2012-11-16
NZ581917A (en) 2011-04-29
WO2008148754A2 (en) 2008-12-11
WO2008148754A3 (en) 2009-03-05
AU2008258639B2 (en) 2012-07-05
US20130252883A1 (en) 2013-09-26
ZA200908262B (en) 2010-08-25
KR20100021496A (ko) 2010-02-24
US8476224B2 (en) 2013-07-02
BRPI0812340A2 (pt) 2015-01-27
EA200901613A1 (ru) 2010-06-30
CL2008001613A1 (es) 2009-05-15
CN101772506B (zh) 2014-02-12
PE20090318A1 (es) 2009-04-17
EP2170907A2 (en) 2010-04-07
MX2009013214A (es) 2010-01-15

Similar Documents

Publication Publication Date Title
CO2020007218A2 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CR20160015A (es) Compuestos de éster boronato y composiciones farmacéuticas de los mismos
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
PE20151023A1 (es) Triazolopirazinas
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
ECSP10010015A (es) Inhibidores de proteasoma
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY32359A (es) Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
GT200900310A (es) Macrociclos y sus usos
CL2011002907A1 (es) Compuestos derivados de nitrilo; sus composiciones farmacéuticas y su uso para el tratamiento de enfermedades hiperproliferativas.
SV2011003839A (es) Agentes antifungicos
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
CL2017002229A1 (es) Inhibidores de bace1.